These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 29254501

  • 21. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R, Hussain A, DeAngelis D.
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [Abstract] [Full Text] [Related]

  • 22. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 23. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.
    Glutsch V, Grän F, Weber J, Gesierich A, Goebeler M, Schilling B.
    J Immunother Cancer; 2019 Jul 12; 7(1):181. PubMed ID: 31300044
    [Abstract] [Full Text] [Related]

  • 24. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
    Cao Y, Afzal MZ, Shirai K.
    BMJ Case Rep; 2021 Aug 20; 14(8):. PubMed ID: 34417242
    [Abstract] [Full Text] [Related]

  • 25. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR, Yoon JH, Kim HK, Kang HC.
    Front Endocrinol (Lausanne); 2020 Aug 20; 11():14. PubMed ID: 32047478
    [Abstract] [Full Text] [Related]

  • 26. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
    Mae S, Kuriyama A, Tachibana H.
    J Emerg Med; 2021 Mar 20; 60(3):342-344. PubMed ID: 33097350
    [Abstract] [Full Text] [Related]

  • 27. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T, Tontivuthikul B, Sintawichai N, Srichomkwun P.
    J Med Case Rep; 2020 Sep 29; 14(1):171. PubMed ID: 32988414
    [Abstract] [Full Text] [Related]

  • 28. A Case of Drug-Induced Severe Endocrinopathies: What Providers in the Emergency Department Need to Know.
    Villarreal J, Townes D, Vrablik M, Ro K.
    Adv Emerg Nurs J; 2018 Sep 29; 40(1):16-20. PubMed ID: 29384770
    [Abstract] [Full Text] [Related]

  • 29. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan 29; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF.
    J Immunother Cancer; 2018 Jul 16; 6(1):73. PubMed ID: 30012206
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
    Irwin DE, Davis B, Bell JA, Galaznik A, Garcia-Ribas I.
    J Comp Eff Res; 2019 Jan 16; 8(2):81-90. PubMed ID: 30547675
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Jan 16; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 36. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
    Zieman D, Frankel AE.
    J Immunother; 2019 Oct 16; 42(8):318-320. PubMed ID: 31318723
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH.
    Eur J Endocrinol; 2018 Feb 16; 178(2):173-180. PubMed ID: 29187509
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Checkpoint inhibition and melanoma: Considerations in treating the older adult.
    Friedman CF, Wolchok JD.
    J Geriatr Oncol; 2017 Jul 16; 8(4):237-241. PubMed ID: 28506536
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.